Open AccessVenetoclax Boosts Benefits of R‐EPOCH in Aggressive B‐Cell Lymphomas
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0569
Subject(s) - chemoimmunotherapy , medicine , venetoclax , epoch (astronomy) , lymphoma , aggressive lymphoma , oncology , refractory (planetary science) , clinical trial , cancer research , leukemia , rituximab , chronic lymphocytic leukemia , stars , physics , astronomy , astrobiology
Adding venetoclax to standard chemoimmunotherapy with R‐EPOCH showed promising antitumor activity in two lymphoma trials: a phase II trial of patients with previously untreated or relapsed/refractory Richter's syndrome and a phase I trial of patients with previously untreated aggressive B‐cell lymphoma.